Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers - Episode 5
Efficacy With NRG1-Directed Agents in NSCLC
D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses clinical efficacy with agents targeted for NRG1-fusion–positive non–small cell lung cancer.
Video Player is loading.
Editor's Note: The correct dosage administration of zenocutuzumab is every 2 weeks.
